Competition intensifies in Forsteo market with 4 latecomers
By Lee, Tak-Sun | translator Alice Kang
21.11.18 06:00:52
가나다라
0
Pharmbio Korea receives approval for Forsteo’s biosimilar… limitations in reimbursement that covers only second-line or subsequent lines of treatment criticized
Fourth biosimilar to enter market after Dong-A ST, Daewon Pharm, BMI Korea…receives mixed expectations in market
▲Teriparatide products Fosteo and Teribone
Products with the same ingredient as the world’s first bone anabolic agent 'Forsteo(Teriparatide),' which was finally able to receive reimbursement in Korea 10 years after its approval, are rapidly entering the market.Domestic pharmaceutical companies are occupying the follow-on market with their Forsteo latecomers. Already 4 teriparatide products have entered the market.
On the 16th, the MFDS approved Pharmbio Korea’s teriparatide biosimilar. The product contains the same teriparatide ingredient as Forster and is indicated for the treatment of osteoporosis in women and men.
The drug was approved as a biosimilar after demonstrating its bioequivalence to Forsteo. Forsteo
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)